Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Cash from Operations (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Cash from Operations for 16 consecutive years, with 979523.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 7.13% to 979523.0 in Q4 2025 year-over-year; TTM through Oct 2025 was 4523768.0, a 133.41% decrease, with the full-year FY2025 number at 2978296.0, down 38.43% from a year prior.
  • Cash from Operations was 979523.0 for Q4 2025 at PharmaCyte Biotech, up from 1993981.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 342959.0 in Q3 2023 to a low of 1993981.0 in Q3 2025.
  • A 5-year average of 877187.15 and a median of 959913.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 131.63% in 2023, then crashed 434.15% in 2025.
  • PharmaCyte Biotech's Cash from Operations stood at 1385613.0 in 2021, then crashed by 35.63% to 1879264.0 in 2022, then decreased by 5.59% to 1984354.0 in 2023, then surged by 46.85% to 1054735.0 in 2024, then grew by 7.13% to 979523.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Cash from Operations are 979523.0 (Q4 2025), 1993981.0 (Q3 2025), and 1040371.0 (Q2 2025).